Sullivan
Microsoft has discontinued support for Internet Explorer. To access the Sullivan website, please install a modern browser like Microsoft Edge or Google Chrome.

Biography

  • Sales agent counsel in a $6 billion up-sized At-The-Market (ATM) public offering of common stock by a global marketing partner to leading sportsbooks and online casino gaming operators.
  • Placement agent counsel in a $1.5 billion registered direct offering and concurrent PIPE offering of common stock (or equivalent), and sales agent counsel in a $1 billion At-The-Market (ATM) public offering of common stock, by a leading provider of digital asset trading and payment solutions.
  • Sales agent counsel in a $100 million At-The-Market (ATM) public offering of common stock by an innovative energy infrastructure company developing cutting-edge data centers.
  • Placement agent counsel in a $425 million private placement of common stock by a global marketing partner to leading sportsbooks and online casino gaming operators.
  • Placement agent counsel in a $100 million private placement of common stock by a brand owner of consumer products and cryptocurrency portfolios
  • Sales agent counsel in a $700 million At-The-Market (ATM) public offering of common stock of a leading clinical stage and commercial biopharmaceutical company
  • Issuer counsel in a $75 million At-The-Market (ATM) public offering of common stock of a leading developer of placenta-based cell therapy products
  • Issuer counsel in a $28.6 private placement of preferred stock of a Nasdaq listed leading global digital health company with mobile health and big data solutions
  • Placement agent counsel in a $49.8 million offering of common stock and warrants of a Canadian issuer that is one of the largest and longest-operating, vertically integrated greenhouse growers in North America
  • Placement agent counsel in a $16 million offering of common stock and warrants by a company that markets and sells a wide variety of complementary products and services to customers operating in the regulated medical and recreational cannabis and cannabidiol (CBD) industries
  • Issuer counsel in a $21 million offering of common stock and warrants by a leading developer of placenta-based cell therapy products
  • Issuer counsel in a $56 million Series A financing of a private biotech company committed to developing vaccines against pathogens acquired by mucosal infection
  • Issuer counsel in a $50 million private placement of preferred stock by a private clinical-stage biopharmaceutical company focused on developing and commercializing novel, locally administered therapies
  • Underwriter counsel in a $16 million public offering by a late-stage biotechnology company developing immunotherapies that enlist the body's own immune system to fight cancer
  • Underwriter counsel in a $8 million public offering of common stock and warrants by an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers
  • Underwriter counsel in a $7 million offering of common stock and warrants by a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products

Matters

  • Sales agent counsel in a $6 billion up-sized At-The-Market (ATM) public offering of common stock by a global marketing partner to leading sportsbooks and online casino gaming operators.
  • Placement agent counsel in a $1.5 billion registered direct offering and concurrent PIPE offering of common stock (or equivalent), and sales agent counsel in a $1 billion At-The-Market (ATM) public offering of common stock, by a leading provider of digital asset trading and payment solutions.
  • Sales agent counsel in a $100 million At-The-Market (ATM) public offering of common stock by an innovative energy infrastructure company developing cutting-edge data centers.
  • Placement agent counsel in a $425 million private placement of common stock by a global marketing partner to leading sportsbooks and online casino gaming operators.
  • Placement agent counsel in a $100 million private placement of common stock by a brand owner of consumer products and cryptocurrency portfolios
  • Sales agent counsel in a $700 million At-The-Market (ATM) public offering of common stock of a leading clinical stage and commercial biopharmaceutical company
  • Issuer counsel in a $75 million At-The-Market (ATM) public offering of common stock of a leading developer of placenta-based cell therapy products
  • Issuer counsel in a $28.6 private placement of preferred stock of a Nasdaq listed leading global digital health company with mobile health and big data solutions
  • Placement agent counsel in a $49.8 million offering of common stock and warrants of a Canadian issuer that is one of the largest and longest-operating, vertically integrated greenhouse growers in North America
  • Placement agent counsel in a $16 million offering of common stock and warrants by a company that markets and sells a wide variety of complementary products and services to customers operating in the regulated medical and recreational cannabis and cannabidiol (CBD) industries
  • Issuer counsel in a $21 million offering of common stock and warrants by a leading developer of placenta-based cell therapy products
  • Issuer counsel in a $56 million Series A financing of a private biotech company committed to developing vaccines against pathogens acquired by mucosal infection
  • Issuer counsel in a $50 million private placement of preferred stock by a private clinical-stage biopharmaceutical company focused on developing and commercializing novel, locally administered therapies
  • Underwriter counsel in a $16 million public offering by a late-stage biotechnology company developing immunotherapies that enlist the body's own immune system to fight cancer
  • Underwriter counsel in a $8 million public offering of common stock and warrants by an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers
  • Underwriter counsel in a $7 million offering of common stock and warrants by a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products